Locations:
Search
A co-author explains some of the key McDonald criteria revisions
The BTK inhibitor tolebrutinib meets its primary endpoint in phase 3 HERCULES trial
Meaningful characterization is critical to advancing research and care, review authors contend
Guidance from international committee on differential diagnoses and diagnostic approach
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
New phase 1 trial showcases Neurological Institute’s interdisciplinary study capabilities
It’s time to get familiar with this emerging demyelinating disorder
Heightened awareness of this rare disorder may lead to better diagnosis and treatment progress
Insights on the decision process for selecting a treatment approach
New reports focus on neuroimaging biomarkers and features of atypical presentations
Perhaps, with caveats: sNfL elevation has low sensitivity and lags MRI activity by at least a month
Advertisement
Advertisement